Health care inclusion: a reasonably narrow set of outcomes?
According to Wellington’s health care inclusion team, as in prior election years, the 2024 US presidential and congressional elections will likely contribute to heightened volatility in health care markets given the historical relationship between politics and health care policy. That said, the team believes that the range of outcomes is narrower in the current election cycle compared to prior election cycles. This is in part because Trump has been president before, giving us a track record on his approach to health care, while Harris is more likely to continue the policies of her predecessor. Furthermore, as it stands today, health care is a lower-priority voter concern, though an important part of cost-of-living concerns, which reduces the likelihood of large policy or major structural changes in the health care system. As a result, this should create a more predictable environment that can enable companies across health care subsectors to execute.
All that said, the health care inclusion team does see some relative winners and losers across the health care industry. The team believes there are bipartisan health care priorities that should continue regardless of the election outcome. These include advancing value-based care initiatives, expanding access to behavioural health care, pharmacy benefit manager (PBM) reform and drug pricing scrutiny.
Under a Democratic sweep scenario, Kamala Harris may propose expanding the annual number of Medicare drugs subject to negotiation and, if passed, this could impact the earnings profile of the biopharma industry. In addition, the health care inclusion team would expect companies exposed to Medicaid and healthcare exchanges to continue to experience a favourable political backdrop with regard to funding and subsidies. Medicare Advantage is more likely to face continued headwinds, albeit manageable.
Under a divided government with Harris as president, the team expects existing drug pricing legislation to remain intact with minimal changes.
Under a divided government with Trump as president or a Republican sweep scenario, the focus on drug pricing may be more limited. On the other hand, repealing the IRA under a Republican sweep scenario is also unlikely due to significant federal spending requirements.
Trends and transformation distilled: Our 2024 outlook in brief
Continue readingMultiple authors